Business Context and Reporting Period
This Form 8-K Current Report was filed by Alaunos Therapeutics, Inc. (TCRT) on July 17, 2025, covering events occurring on July 15, 2025. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and adjustments to Board committee leadership.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
- Director Appointment: Michael A. Jerman was appointed as a director effective July 15, 2025, filling the vacancy left by the resignation of Dale Curtis Hogue.
- Committee Assignments: Mr. Jerman was appointed to the Audit Committee and the Compensation Committee, replacing Holger Weis (who recently became CEO). Mr. Jerman will serve as the Chair of the Audit Committee.
- Independence: The Board determined Mr. Jerman meets independence requirements under Nasdaq and SEC standards.
Compensation and Governance Details
Mr. Jerman's compensation package includes:
- Cash Retainer: $40,000 annual base cash retainer.
- Committee Fees: $15,000 for Audit Committee Chair and $7,500 for Compensation Committee member.
- Equity Grants:
- Initial Grant: Stock option for 10,000 shares, vesting monthly over 36 months starting August 15, 2025.
- Annual Grant: Stock option for 3,200 shares (prorated for 2025), with unvested portions vesting fully prior to the 2026 annual general meeting.
- Indemnification: An indemnification agreement was executed, consistent with those for other directors.
Investor Verification Checklist
- Verify the resignation details of former director Dale Curtis Hogue in prior filings.
- Confirm the impact of Holger Weis's transition to CEO on Board committee composition.
- Review the Company's 2020 Equity Incentive Plan for specific change-in-control vesting terms applicable to Mr. Jerman.
- Check subsequent filings for the 2026 annual general meeting date to confirm full vesting timelines for the Annual Grant.